Drugs such as monoclonal antibodies (anti-CD20), anti-CD19 bi-specific T cell binding agents, and anti-CD22 antibody-drug conjugates have shown unexpected results both in the prophase and R/R settings and continue to change the treatment paradigm for ALL (8–10). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.